Mimedx Group vs Organogenesis Holdings
Organogenesis Holdings is the larger business, with $564m of revenue in fiscal 2025 against $419m for Mimedx Group (1.3 times as much). Mimedx Group grew faster (20.0% against 17.0%). Mimedx Group kept more of each dollar of sales as profit: a net margin of 11.6% against 6.6%.
| Latest fiscal year | Mimedx GroupMDXG, 2025 | Organogenesis HoldingsORGO, 2025 |
|---|---|---|
| Revenue | $419m | $564m |
| Revenue growth | 20.0% | 17.0% |
| Net income | $48.6m | $37.0m |
| Operating margin | — | 7.9% |
| Net margin | 11.6% | 6.6% |
| Return on equity | 21.6% | 13.2% |
| Free cash flow | $74.0m | −$24.5m |
| Cash | $166m | $93.7m |
| Total debt | $18.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 808 | 854 |
| Market value | $462m | $109m |
| Price vs our value range | Below our value range | — |
| Moat score | 59 (Moderate) | 56 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 4 sales |